NUWE vs. HSDT, TIVC, AUVI, NDRA, QLGN, ALLR, PRFX, ATNF, PXMD, and OSAP
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Helius Medical Technologies (HSDT), Tivic Health Systems (TIVC), Applied UV (AUVI), ENDRA Life Sciences (NDRA), Qualigen Therapeutics (QLGN), Allarity Therapeutics (ALLR), PainReform (PRFX), 180 Life Sciences (ATNF), PaxMedica (PXMD), and ProSomnus (OSAP).
Helius Medical Technologies (NASDAQ:HSDT) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
Helius Medical Technologies received 1 more outperform votes than Nuwellis when rated by MarketBeat users. Likewise, 57.14% of users gave Helius Medical Technologies an outperform vote while only 50.00% of users gave Nuwellis an outperform vote.
Helius Medical Technologies has higher earnings, but lower revenue than Nuwellis. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Nuwellis has a net margin of -202.97% compared to Nuwellis' net margin of -1,374.22%. Nuwellis' return on equity of -221.11% beat Helius Medical Technologies' return on equity.
18.6% of Helius Medical Technologies shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 7.3% of Helius Medical Technologies shares are owned by company insiders. Comparatively, 0.9% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Helius Medical Technologies has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
In the previous week, Helius Medical Technologies had 1 more articles in the media than Nuwellis. MarketBeat recorded 10 mentions for Helius Medical Technologies and 9 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.74 beat Helius Medical Technologies' score of 0.14 indicating that Helius Medical Technologies is being referred to more favorably in the media.
Helius Medical Technologies currently has a consensus target price of $24.00, suggesting a potential upside of 1,372.39%. Given Nuwellis' stronger consensus rating and higher probable upside, equities analysts plainly believe Helius Medical Technologies is more favorable than Nuwellis.
Summary
Helius Medical Technologies beats Nuwellis on 14 of the 18 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuwellis Competitors List
Related Companies and Tools
